A small molecule Active Pharmaceutical Ingredient (API) is a low molecular weight organic compound, which may help to control biological process. Most of the small molecules can be administered orally and are most likely to be absorbed by the body. Owing to its small size it has properties of rapid diffusibility to reach the intracellular site of action.
Market Dynamics
Growing expansion of small molecule API manufacturers in the Asia Pacific region is a major factor driving the small molecule API market growth. For instance, BASF is planning to build a new specialty amines plant at its existing site in Nanjing Chemical Industry Park, China. This new multi-product plant will be able to manufacture 21,000 metric tons of amines year, and it extends BASF’s amines portfolio at the specialty amines complex in Nanjing. The plant is scheduled to stream by 2019. Moreover the small molecule API manufacturers have planned to add global sales and business development staff, followed by quality, regulatory, and project management teams, which have positively influenced growth of the market.
However, stringent regulatory policies for API manufacturing may hinder the market growth. Stringent global regulatory policies on quality assessments of small molecule API manufacturing, facility certification, and increased supply chain security issues across emerging countries have a large impact on the cost of final small molecule API products. The new entrants willing to enter into small molecule API manufacturing are facing financial challenges, owing to aforementioned factors.
Key features of the study:
- This report provides in-depth analysis of the small molecule API market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2018 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, impact analysis, PEST analysis, collaborations, mergers and acquisitions, regulatory scenarios, technological advancements, steps to manufacture small molecule API, major suppliers of small molecule APIs, market trends
- It profiles key players in the global small molecule API market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include, Lonza, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Aesica Pharmaceuticals Ltd., Albemarle Corporation, Cambrex Corporation, BASF SE, Gland Pharma Limited, Gilead Sciences, Inc., AstraZeneca Plc, Baxter International Inc., Boehringer Ingelheim International GmbH, Celgene Corporation, Piramal Pharma Solutions, Recipharm AB, Evonik Industries AG, Glenmark Pharmaceuticals Limited, Siegfried AG, AbbVie Contract Manufacturing, Aurinia Pharmaceuticals Inc., Bayer AG, Patheon, CordenPharma International
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics.
- The global small molecule API market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the small molecule API market
Detailed Segmentation:
- Global Small Molecule API Market, By API Type:
- Global Small Molecule API Market, By Category:
- Analgesic
- Anesthetics
- Anticonvulsants
- Antimetabolites
- Antibacterial
- Alkylating Agents
- Others
- Global Small Molecule API Market, By Geography:
- North America
- By API Type:
- By Category:
- Analgesic
- Anesthetics
- Anticonvulsants
- Antimetabolites
- Antibacterial
- Alkylating Agents
- Others
- By Country:
- Latin America
- By API Type:
- By Category:
- Analgesic
- Anesthetics
- Anticonvulsants
- Antimetabolites
- Antibacterial
- Alkylating Agents
- Others
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By API Type:
- By Category:
- Analgesic
- Anesthetics
- Anticonvulsants
- Antimetabolites
- Antibacterial
- Alkylating Agents
- Others
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By API Type:
- By Category:
- Analgesic
- Anesthetics
- Anticonvulsants
- Antimetabolites
- Antibacterial
- Alkylating Agents
- Others
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By API Type:
- By Category:
- Analgesic
- Anesthetics
- Anticonvulsants
- Antimetabolites
- Antibacterial
- Alkylating Agents
- Others
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By API Type:
- By Category:
- Analgesic
- Anesthetics
- Anticonvulsants
- Antimetabolites
- Antibacterial
- Alkylating Agents
- Others
- By Country:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Lonza *
- Company Overview
- Product Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Aesica Pharmaceuticals Ltd.
- Albemarle Corporation
- Cambrex Corporation
- BASF SE
- Gland Pharma Limited
- Gilead Sciences, Inc.
- AstraZeneca Plc
- Baxter International Inc.
- Boehringer Ingelheim International GmbH
- Celgene Corporation
- Piramal Pharma Solutions
- Recipharm AB
- Evonik Industries AG
- Glenmark Pharmaceuticals Limited
- Siegfried AG
- AbbVie Contract Manufacturing
- Aurinia Pharmaceuticals Inc.
- Bayer AG
- Patheon
- CordenPharma International
“*” marked represents similar segmentation in other categories in the respective section.
